Eikon, a biotech company, recently raised $351 million, making it one of the largest fundraising events in the biotech sector this year. This funding will help Eikon advance its research and development efforts, though specific drug names were not mentioned in the announcement.
This financing deal is the second-biggest of the year for one of the nearly 24 venture capital firms monitored by BioPharma Dive. It involves investments in the pharmaceutical sector, potentially including companies that develop medications such as Lipitor or Zoloft.